# Final trial results show promising long-term survival with lenvatinib plus pembrolizumab in advanced thymic tumors

Source: [Medical Xpress - latest medical and health news stories](https://medicalxpress.com/news/2026-11-trial-results-term-survival-lenvatinib.html) · 2026-11-13 · Medicine
Page: https://themorning.science/story/final-trial-results-show-promising-long-term-survival-with-lenvatinib-plus-pembr-fdca9feeba76adfc
Kind: research · Impact: medium

## In brief

- Final results from the phase 2 PECATI clinical trial were reported.
- The trial tested lenvatinib plus pembrolizumab in previously treated advanced B3-thymoma and thymic carcinoma.
- The reported outcomes are encouraging long-term survival figures for the combination.

## Why it matters

It provides long-term survival data for a combination therapy in rare, hard-to-treat thymic tumors, where evidence is limited.

## Timeline

- 2026-11-13: Final results from the PECATI phase 2 trial reported by Medical Xpress

## Coverage

- [Final trial results show promising long-term survival with lenvatinib plus pembrolizumab in advanced thymic tumors](https://medicalxpress.com/news/2026-11-trial-results-term-survival-lenvatinib.html) — Medical Xpress - latest medical and health news stories, 2026-11-13

Tags: oncology, thymic tumors, immunotherapy, clinical trial, lenvatinib, pembrolizumab

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science